G1 Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
05 Septembre 2023 - 5:00PM
G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology
company, today announced that G1’s Communications Officer Will
Roberts will provide a corporate presentation on September 12,
2023, at 9:30 AM EDT during the H.C. Wainwright 25th Annual Global
Investment Conference.
The webcast of the event will be accessible on the Events &
Presentations page of http://www.g1therapeutics.com.
About G1 TherapeuticsG1 Therapeutics, Inc. is a
commercial-stage biopharmaceutical company focused on the
development and commercialization of next generation therapies that
improve the lives of those affected by cancer, including the
Company’s first commercial product, COSELA® (trilaciclib). G1 has a
deep clinical pipeline and is executing a development plan
evaluating trilaciclib in a variety of solid tumors, including
breast, lung, and bladder cancers. G1 Therapeutics is based in
Research Triangle Park, N.C. For additional information, please
visit www.g1therapeutics.com and follow us on Twitter
@G1Therapeutics.
G1 Therapeutics® and the G1 Therapeutics logo and COSELA® and
the COSELA logo are trademarks of G1 Therapeutics, Inc
Contacts:Will RobertsCommunications OfficerVice
President, Investor Relations & Corporate
Communications919-907-1944 wroberts@g1therapeutics.com
G1 Therapeutics (NASDAQ:GTHX)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
G1 Therapeutics (NASDAQ:GTHX)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024